Who We Are
Genomic engineering, also known as gene editing, involves the manipulation of cellular DNA in order to repair or delete a gene’s function. New and exciting developments with CRISPR systems for gene editing have sparked a rush to bring this life saving technology to the clinic. Hundreds of millions of dollars have been raised by our competitors for this purpose. ESI seeks to cater to a global market of clients currently using CRISPR products by offering a unique portfolio of products and services.
Moreover, ESI has generated a novel and proprietary gene editing technology that resolves barriers found within the current CRISPR system.
What We Sell:
ESI sells products and servcies for cell engineering and for gene editing. ESI also sells chemokine related products and vendors services for next generation sequencing.
Who We Sell To:
Research Institutions (Government and Private) focused on
Colleges and Universities